A phase I study of docetaxel and bexarotene

Chemotherapy

Volumn 54, Issue 2, 2008, Pages 125-130

  Wildi, Jonathan D ^a   Baggstrom, Maria Q ^a   Suresh, Rama ^a   Read, William ^b   Fracasso, Paula M ^a   Govindan, Ramaswamy ^a  

^a USA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bexarotene; Docetaxel; Lung cancer; Non small cell lung cancer; Phase I trial

Indexed keywords

ATORVASTATIN; BEXAROTENE; CARBOPLATIN; DEXAMETHASONE; DOCETAXEL; GEMFIBROZIL; GROWTH FACTOR; PACLITAXEL; THYROTROPIN; THYROXINE;

ADULT; AGED; ALOPECIA; ANEMIA; ANGIOSARCOMA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; BONE METASTASIS; BRAIN METASTASIS; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG TOLERABILITY; EDEMA; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HYPERTRIGLYCERIDEMIA; HYPOTHYROIDISM; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALAISE; MALE; MAXIMUM TOLERATED DOSE; METABOLIC DISORDER; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN MANIFESTATION; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEMALE; HUMANS; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; TAXOIDS; TETRAHYDRONAPHTHALENES;

EID: 41349086261     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000119706     Document Type: Article

References (22)

1. Mori K, Kamiyama Y, Kondo T, et al: A phase II study of docetaxel and infusional cisplatin in advanced non-small-cell lung cancer. Chemotherapy 2005;51:120-125.
2. Meyer F, Lueck A, Hribascheck A, et al: Phase I trial using weekly administration of gemcitabine and docetaxel with advanced pancreatic carcinoma. Chemotherapy 2004;50:289-296.
3. Hainsworth JD, Burris HA 3rd, Erland JB, et al: Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol 1998;16:2164-2168.
4. Hainsworth JD: Practical aspects of weekly docetaxel administration schedules. Oncologist 2004;9:538-545.
5. Hainsworth JD, Burris HA 3rd, Litchy S, et al: Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma. A Minnie Pearl Cancer Research Network Phase II Trial. Cancer 2000;89:328-333.
6. Roszkowski K, Pluzanska A, Krzakowski M, et al: A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naïve patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer 2000;27:145-157.
7. Burstein HJ, Maola J, Younger J, et al: Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 2000;18:1212-1219.
8. Graziano F, Catalano V, Baldelli AM, et al: A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer. Ann Oncol 2000;11;1263-1266.
9. Schrijvers D, Vroman P, Dyck J, et al: Weekly docetaxel in patients with recurrent and/or metastatic head and neck cancer. Proc Am Soc Clin Oncol 2001;21:A2544.
10. Ramos M, Gonzalez-Ageitos A, Vicente J: Weekly docetaxel for metastatic breast cancer progressing after anthracycline treatment. Proc Am Soc Clin Oncol 2000;19:A445.
11. Boehm MF, Zhang L, Badea BA, et al: Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids. J Med Chem 1994;37:2930-2941.
12. Mangelsdorf DJ, Ong ES, Dyck JA, Evans RM: Nuclear receptor that identifies a novel retinoic acid response pathway. Nature 1990;345:224-229.
13. Mangelsdorf DJ, Thummel C, Beato M, et al: The nuclear receptor superfamily: the second decade. Cell 1995;83:835-839.
14. Farol LT, Hymes KB: Bexarotene: a clinical review. Expert Rev Anticancer Ther 2004;4:180-188.
15. Duvic M, Hymes K, Heald P, et al: Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 2001;19:2456-2471.
16. Miller VA, Benedetti FM, Rigas JR, et al: Initial clinical trial of a selective retinoid X receptor ligand, LGD1069. J Clin Oncol 1997;15:790-795.
17. Rizvi NA, Marshall JL, Dahut W, et al: A phase I study of LGD1069 in adults with advanced cancer. Clin Cancer Res 1999;5:1658-1664.
18. Khuri FR, Rigas JR, Figlin RA, et al: Multi-institutional phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer. J Clin Oncol 2001;19:2626-2637.
19. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
20. Govindan R, Crowley J, Schwartzberg L, et al: Phase II trial of bexarotene capsules in patients with non-small-cell lung cancer (NSCLC) who have failed at least 2 prior systemic therapies for stage IIIB/IV disease (abstract). J Clin Oncol 2005;23(suppl):7116.
21. Edelman MJ, Smith R, Hausner P, et al: Phase II trial of the novel retinoid, bexarotene, and gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5774-5778.
22. Tyagi P: Bexarotene in combination with chemotherapy fails to prolong survival in patients with advanced non-small-cell lung cancer: results from the SPIRIT I and II trials. Clin Lung Cancer 2005;7:17-19.